P2Y12 receptor drugs for Atherosclerotic Cardiovascular Disease
2 tracked P2Y12 receptor drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the P2Y12 receptor page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
2 approved / phase 4
Head-to-head evidence: Cangrelor vs Ticagrelor